Trial Profile
A PK Study to Assess the Relative Systemic Exposure to Bimatoprost and Bimatoprost Acid After Administration of a Single 13 mg Bimatoprost Ocular Insert for 1 Week in Medically Stable Adult Subjects With or Without Open-Angle Glaucoma or Ocular Hypertension
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 May 2015
Price :
$35
*
At a glance
- Drugs Bimatoprost (Primary)
- Indications Glaucoma; Ocular hypertension
- Focus Pharmacokinetics
- Sponsors ForSight VISION5
- 18 May 2015 New trial record